A composition and method of preparing the composition for rapid and effective hemostasis is provided. The composition includes a first agent to induce platelet plug formation, a second to induce vasoconstriction and a third agent for activation of coagulation cascade. The composition comprises of 0.01% to 5% of chitosan; 0.01% to 0.25% of potassium aluminum sulphate; and 0.01% to 0.25% calcium salt. The clotting time of the composition is in the range of 30s to 140s. A method of preparing the hemostatic composition is further disclosed. The composition is configured to control hemorrhage from oozing and pressured bleeding injury any site in human/animal body.

A composition and method of preparing the composition for rapid and effective hemostasis is provided. The composition includes a first agent to induce platelet plug formation, a second to induce vasoconstriction and a third agent for activation of coagulation cascade. The composition comprises of 0.01% to 5% of chitosan; 0.01% to 0.25% of potassium aluminum sulphate; and 0.01% to 0.25% calcium salt. The clotting time of the composition is in the range of 30s to 140s. A method of preparing the hemostatic composition is further disclosed. The composition is configured to control hemorrhage from oozing and pressured bleeding injury any site in human/animal body.

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

The composition, advantageously an emulsion or a foam, includes an internal phase dispersed in a hydrophilic continuous phase, the percentage of the internal phase being higher than 50%. The emulsion composition contains nanocrystals of a polysaccharide other than cellulose, advantageously chitin, that are located at the interface between the internal phase and the hydrophilic continuous phase.

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.

The present invention provides a novel biomaterial which is a hybrid, self-assembling biopolymeric networked film that is functionalized through hydrophobic interactions with vesicles loaded with bioactive agents. The biomaterial compound is a polymeric network of hydrophobically modified chitosan scaffolds that is taken from solution and formed as a solid film. This solid state film is capable of hydrophobic interactions with the functionalized vesicles. The vesicles include one or more lamellar structures forming one or more nano-compartments that are capable of containing similar or alternative active moieties within. Use of the film results in a degradation of the chitosan scaffold thereby releasing the active moieties within the vesicles from the scaffold. Application of the current invention occurs through various delivery mechanisms and routes of administration as will be described herein.

The present invention provides a novel biomaterial which is a hybrid, self-assembling biopolymeric networked film that is functionalized through hydrophobic interactions with vesicles loaded with bioactive agents. The biomaterial compound is a polymeric network of hydrophobically modified chitosan scaffolds that is taken from solution and formed as a solid film. This solid state film is capable of hydrophobic interactions with the functionalized vesicles. The vesicles include one or more lamellar structures forming one or more nano-compartments that are capable of containing similar or alternative active moieties within. Use of the film results in a degradation of the chitosan scaffold thereby releasing the active moieties within the vesicles from the scaffold. Application of the current invention occurs through various delivery mechanisms and routes of administration as will be described herein.

The present invention discloses a method comprising administering a monosaccharide and/or polysaccharide as an active ingredient, for decreasing the accumulation of di-carbonyl compounds in the human body. Said monosaccharide is a monomer of said polysaccharide, and the molecular weight of the polysaccharide ranges from 29 kDa to 36 kDa. The monosaccharide and/or polysaccharide can be used to prevent or treat nephritis or diseases associated with di-carbonyl compounds, or other diseases caused by carbonyl-stress, and can also be used to make the relevant drug.